Early data shows the government's $174.5m ”world-leading” free respiratory syncytial virus (RSV) immunisation program for ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

The S&P 500 ended slightly higher on Monday (June 9), extending its gains for a second session, as markets reacted to renewed ...

The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The company said ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Thyme&Tabletm, a family-owned leader in stylish, high-performance homewares at affordable prices, today announced the launch of its first line of premier kitchen appliances ? the perfect balance ...

Sheppard Pratt celebrated the groundbreaking of its future 16-bed Residential Crisis Program on its Baltimore/Washington Campus with a ceremony on Monday, June 9. The program represents a significant ...

The letter was signed by 92 NIH scientists and many more who remained anonymous across all 27 of the agency's divisions.

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...